Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

AVTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Avalo Therapeutics, Inc.NASDAQ: AVTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $14.05M rose 54.0% year over year, behind the +74.4% change in trailing-twelve-month research & development. Sequentially, it rose 5.9% from the prior quarter. Over 3 fiscal years it compounded at +17.0% a year.

Context

  • Research & development amounted to 84888.1% of revenue in FY2025, up 73079.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +54.0% toward the trailing-twelve-month pace of +74.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.05M+5.9% QoQ
Last fiscal yearDec 2025
$50.08M-3.8% YoY
LTMMar 2026
$55.01M+74.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+54.0%——
1 year-3.8%——
3-year CAGR+17.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
50.08M USD
Year-over-year change
-3.8%
4-year CAGR
-4.3%

Research & Development vs competitors

How AVTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +74.4% is the highest of 10, against a peer median of +11.4%.
  • Research & development amounts to 93235.6% of revenue for AVTX, versus a peer median of 265.3%.
AVTX Competitors
Research & Development for AVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$259.72M USD+46.3%+43.1%287.0%
XNCRXencor, Inc.LTM Jun 2026$255.77M USD+11.4%+6.3%243.6%
ANABAnaptysBio, Inc.LTM Mar 2026$128.65M USD-23.4%+15.3%55.4%
IMUXImmunic, Inc.LTM Mar 2026$86.08M USD+3.9%+4.8%—
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$69.93M USD+20.4%+34.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$56.72M USD+60.6%-12.2%677.9%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$55.01M USD+74.4%+17.0%93235.6%
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€39.31M EUR+49.4%——
IFRXInflaRx N.V.LTM Mar 2026€22.87M EUR-34.8%-11.8%77989.1%
QTTBQ32 Bio Inc.LTM Mar 2026$15.25M USD-66.4%-18.8%28.4%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding AVTX) —+11.4%+5.5%265.3%

Competitors are the stored peer set for AVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5.4M18.05M1.92M441K59K
Cost of Revenue1.49M3.43M1.28M(366K)0
Gross Profit3.91M14.62M640K807K59K
Gross Margin72.4%81.0%33.3%183.0%100.0%
Research & Development59.84M31.31M13.78M52.08M50.08M
Selling, General & Admin24.66M20.71M10.3M17.24M22.9M
Operating Expenses86.04M52.06M27.99M69.32M72.98M
Depreciation & Amortization1.66M166K158K169K344K
EBITDA(80.5M)(37.29M)(23.29M)(34.85M)(77.75M)
EBITDA Margin-1491.2%-206.6%-1210.3%-7901.6%-131779.7%
Operating Income(82.13M)(37.44M)(27.35M)(68.51M)(72.93M)
Operating Margin-1521.6%-207.4%-1421.6%-15535.6%-123601.7%
Interest Income0003.32M4.35M
Interest Expense2.39M4.17M3.42M00
Other Income / Expenses(2.41M)(4.19M)(4.18M)33.5M(5.17M)
Income Before Tax(84.55M)(41.63M)(31.53M)(35.02M)(78.09M)
Pre-Tax Margin-1566.2%-230.6%-1638.8%-7939.9%-132362.7%
Income Tax Expense(196K)28K14K114K165K
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Net Margin-1563.1%-230.8%-1639.5%-7965.8%-132642.4%
EPS (Basic)(2,330.66)(1,062.65)(113.58)(4.32)(5.84)
EPS (Diluted)(2,330.66)(1,062.65)(113.58)(3.26)(5.84)
Weighted Avg Shares36.19K39.2K277.73K8.13M13.4M
Weighted Avg Shares (Diluted)36.19K39.2K277.73K10.78M13.4M

Avalo Therapeutics, Inc.

NASDAQ:AVTX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.